EMA's Revised ATMP Evaluation Procedure Gets Industry

EU pharmaceutical companies believe the revisions the European Medicines Agency has made to its procedure for evaluating gene and cell therapy products addresses the specific needs of advanced therapy developers They have also welcomed in principle a revised EMA guideline on the follow-up and risk management of such products

Request A Quotation!

Caught in the Gap: ATMP manufacture in Academia

ATMP within the European Union (EU) to facilitate their access to the EU market and to with the general scope of the Community pharmaceutical legislation laid down in Title II of Directive 2001/83/EC" If an ATMP is not „prepared industrially or manufactured by a

Request A Quotation!

How to develop a fictitious combined ATMP regarding non

2 Overview of the legal and regulatory landscape governing ATMP 2 1 Legislation The following sections aim at providing an overview of the complex legal landscape regarding both legally binding and non-binding provisions and recommendations that determine the way of a combined ATMP with an integral medical device part from non-

Request A Quotation!

Research tissue banks and research databases

11/21/2019Research tissue banks A research tissue bank or biobank is a collection of human tissue or other biological material which is stored for potential research use beyond the life of a specific project with ethical approval or for which ethical approval is pending

Request A Quotation!

Position paper to current legislation about development

Promising new approaches are developing The new legislation EG 1394/2007 about advanced therapy medicinal products (ATMP) entered into force as from December 30 2008 determining specific rules for registration and surveillance of medicinal products for new therapies

Request A Quotation!

Italy – Rare Impact : Rare Impact

A review of the challenges and proposals for improving patient access to advanced therapeutic medicinal products in Italy Executive Summary RARE IMPACT is a multi-stakeholder initiative working to improve patient access to advanced therapy medicinal products (ATMPs) This patient-focused initiative aims to assess challenges and propose actionable solutions to concerns regarding access to these

Request A Quotation!

Clinical Trials of Investigational Medicinal Products

2/5/2020Legislation sets out how drug trials are approved conducted monitored and reported Protecting and promoting the interests of patients and the public in health research This site uses cookies By continuing to browse the site you are agreeing to our

Request A Quotation!

Accidents du travail et maladies professionnelles (AT

Accidents du travail Aux termes de l'article L 411-1 du Code de la Scurit sociale est considr comme accident du travail quelle qu'en soit la cause l'accident survenu par le fait ou l'occasion du travail toute personne salarie ou travaillant quelque titre ou en quelque lieu que ce soit pour un ou plusieurs employeurs ou chefs d'entreprise

Request A Quotation!

Review of the ATMP Regulation

• ATMP Regulation is a milestone • Problems arise where the legislation comes to its border to national legislations or other provisions: – Hospital exemption – Classification – Regulation/handling of GMOs • Problems arise in daily practice with the new procedures and special product scenarios

Request A Quotation!

Regulation of stem cell research in the United Kingdom

When a cell therapy is deemed to be a Medicinal Product (MP) including an Advanced Therapy Medicinal Product (ATMP) or Investigational Medicinal Product (IMP) the QS regulations will apply for the donation procurement and testing of tissues and cells

Request A Quotation!

Implementing ATMP Legislation Is EMEA Priority This Year

Implementing ATMP Legislation Is EMEA Priority This Year March 27 2009 One of the European Medicines Agency's (EMEA) top priorities this year will be the implementation of 2007 legislation on advanced-therapy medicinal products (ATMPs)

Request A Quotation!

Comits de l'EMA : Comit des mdicaments de thrapie

Introduction Le Comit des mdicaments de thrapie innovante () de l'Agence europenne des mdicaments (EMA) value la qualit la scurit et l'efficacit des mdicaments de thrapie innovante (advanced-therapy medicinal products ATMP) Les ATMP sont des mdicaments usage humain qui sont fabriqus partir de gnes et de cellules ou de tissus ils regroupent les

Request A Quotation!

Unravelling the Complexity of EU's ATMP Regulatory

ATMP development Initially the regulation seemed to have little impact on the number of advanced medicines on the market after the start of its implementation in early 2009 By mid-2013 there were only four marketing authorizations from 10 applications in the three ATMP categories of gene therapy somatic cell therapy and tissue engineering

Request A Quotation!

ATMP – Scope International AG

ATMP differ from other medicines As they are based on chemical entities or are of biological / biotechnology origin they require special legislation when it comes to market authorization Therefore this product class covering different new therapeutic strategies requires special knowledge and

Request A Quotation!

Daniel Rabbie Regulatory Affairs Manager July 2018

EU Regulatory Network • European Commission (EC) (DG SANTE) – Propose and amend legislation for the entire sector 1 Regulations –self-executing and binding to all Member States (MS) no national changes allowed 2 Directives –required output is binding but transposition up to MS to interpret locally (more leeway) – Grants legally binding marketing authorisation valid in all EU

Request A Quotation!

Unravelling the Complexity of EU's ATMP Regulatory

ATMP development Initially the regulation seemed to have little impact on the number of advanced medicines on the market after the start of its implementation in early 2009 By mid-2013 there were only four marketing authorizations from 10 applications in the three ATMP categories of gene therapy somatic cell therapy and tissue engineering

Request A Quotation!

Long term thinking: Advanced Therapy Medicinal Products

ATMP Pan-UK Pharmacy working group iMATCH Stem Cell Lab and Specialist Pharmacy Service (SPS) A list of Actions were identified: • Creation and implementation of an ATMP policy • Oversight of the SCL for licensed products as• per current clinical trial processes: o Audit to SCL management systems and processes performed by Pharmacy

Request A Quotation!
Copyright © 2014. All rights reserved.
^ Back to Top